In recent years, the discovery of immune checkpoints and the development of their inhibitors have revolutionized the treatment of NSCLC, including programmed cell death protein-1 (PD-1) and programmed cell death protein ligand-1 (PD-L1). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.